Vandortuzumab vedotin

Cat. No. M24699

All AbMole products are for research use only, cannot be used for human consumption.

Synonym:

DSTP 3086S; RG 7450; MSTP2109A

Size	Price	Availability
100ug	USD 600 USD600	1-2 Weeks
1mg	USD 1200 USD1200	1-2 Weeks

Free Delivery on orders over USD 500 Bulk Inquiry?

Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer.

CAS Number	1471985-92-8
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.

Related Antibody-Drug Conjugates (ADCs) Products
Oregovomab-MMAE Oregovomab-MMAE is an antibody-drug conjugate (ADC).
Patritumab-MMAE Patritumab-MMAE is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab attached to MMAE.
Depatuxizumab mafodotin Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) which specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can induce cell death in glioma cell lines overexpressing EGFR or EGFRvIII.
Ozuriftamab vedotin Ozuriftamab vedotin (BA3021) is an antibody-drug conjugate (ADC), it is composed of receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab and VcMMAE.
Glembatumumab vedotin Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate (ADC) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects.

Catalog